Search Videos and More
News
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This is a multicenter randomized control trial evaluating novel BTK degrader (BGB-16673) versus standard of care pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had progressive disease on a prior line containing a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patient are allowed but not required to have previously received venetoclax (or other BCL2 directed therapy).
News
Surgery With or Without Neoadjuvant Chemotherapy in High-Risk RetroPeritoneal Sarcoma (STRASS2)
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
News
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)
This trial is a multi-site, single-arm, phase II trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab.
News
Doximity Ask AI May Be Smart, but Trusted Answers Still Depend on Physicians Like Dr. Cohn
A longtime Doximity user, Joshua Cohn, MD, FPMRS, Associate Professor, Department of Urology, Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute provider, had relied on the company’s dialer service for years.
News
Fox Chase Researcher Parth Desai Receives Prestigious ASCO Career Development Award
A Fox Chase Cancer Center researcher has received a prestigious national award to advance a novel immunotherapy strategy aimed at one of oncology's most persistent challenges: tumors that resist immune-based treatments.
News
New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer
A new study from researchers at Fox Chase Cancer Center and collaborators across multiple institutions has identified a hidden subset of lung cancers that behave more like aggressive neuroendocrine tumors than traditional non-small cell lung cancer (NSCLC).
News
First-in-Human Study Tests Gamitrinib Designed to Disrupt Cancer Cells’ Energy Systems
Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell’s “powerhouse.” Unlike healthy cells, cancer cells rely heavily on specialized helper proteins to keep mitochondria functioning under the high stress of rapid growth.
News
Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.
News
Fox Chase – Temple Urologic Institute at AUA 2026
Visit the Fox Chase-Temple Urologic Institute Booth #2464 in the Science & Technology Hall.
News
Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
Temple Health’s Fox Chase Cancer Center, one of only 57 NCI-designated comprehensive cancer centers, today announced a new clinical trial collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services.
Symposium
24th Annual Highlights of the 2025 San Antonio Breast Cancer Symposium
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this education program is designed to help medical, radiation, and surgical oncologists, gynecologists, and radiologists translate the data from key presentations of the 2025 San Antonio Breast Cancer Symposium into practice. New options for the prevention, diagnosis, and treatment of breast cancer and premalignant breast disease will be discussed. In addition, we will address new strategies for optimizing existing treatments.
News
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).